Early research (Phase 1)Study completedNCT00000977
What this trial is testing
Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity
Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 52